Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and innovation, continuing to transform multiple myeloma care BEERSE, BELGIUM, March 27, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted approval for a Type II variation to the labelling for DARZALEX® ...